TopoTarget A/S Symbion Fruebjergvej 3 DK 2100 Copenhagen Denmark Tel: +45 39 17 83 92 Fax: +45 39 17 94 92 CVR-nr: 25695771 www.topotarget.com TopoTarget A/S held an extraordinary general meeting on 23 July 2009 in accordance with the notice convening the meeting issued on 9 July 2009. At the general meeting, the Board of Directors proposed the changes to the Board of Directors set out below: As the current board members Jesper Zeuthen and Torbjörn Bjerke have informed the company that they wish to resign from the Board in connection with the extraordinary general meeting, the Board proposes that Anders Fink Vadsholt, Per Samuelsson and Bo Jesper Hansen be elected to the Company's Board of Directors for the period until the Annual General Meeting to be held in 2010. The Company thanked Jesper Zeuthen and Torbjörn Bjerke for their efforts and commitment while serving on the Board. Anders Fink Vadsholt, Per Samuelsson and Bo Jesper Hansen were unanimously elected to the Board of Directors at the general meeting. Section 49(6) of the Danish Public Companies Act was complied with and the shareholders were given a presentation of Anders Fink Vadsholt, Per Samuelsson and Bo Jesper Hansen. The Company's Board of Directors now consists of the following seven members: Håkan Åström, Jeffrey H. Buchalter, Anders Gersel Pedersen, Ingelise Saunders, Anders Fink Vadsholt, Per Samuelsson and Bo Jesper Hansen. Immediately following the extraordinary general meeting, the Board of Directors elected Håkan Åström as its new chairman. The chairman of the meeting, or a substitute duly appointed by him, was authorised to apply for registration of the resolutions passed and to make any such amendments thereto as may be required by the Danish Commerce and Companies Agency as a condition for registration or approval. TopoTarget A/S For further information, please contact: Peter Buhl Jensen Telephone +45 39 17 83 92 CEO Mobile +45 21 60 89 22 Background information About TopoTarget TopoTarget (OMX: TOPO) is an international biotech company headquartered in Denmark, dedicated to finding ''Answers for Cancer'' and developing improved cancer therapies. The company was founded and is run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. TopoTarget has a broad clinical pipeline but is currently focusing on the development of belinostat, which has shown proof of concept as monotherapy in treating haematological malignancies and positive results in solid tumours where it can be used in combination with full doses of chemotherapy, and is in phase III in PTCL. TopoTarget's expertise in translational research is utilizing its highly predictive in vivo and in vitro cancer models. TopoTarget is directing its efforts on key cancer targets including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors. The company's first marketed product Savene®/Totect® was approved by EMEA in 2006 and the FDA in 2007 and is marketed by TopoTarget's own sales force in Europe and the US. For more information, please refer to www.topotarget.com.